6 news items
MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance
MIRA
22 Jul 24
to a number of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results to differ materially and adversely
Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC
MIRA
15 Jul 24
to differ materially from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs
Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year
MIRA
10 Jun 24
the Company's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking
Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance
MIRA
29 May 24
) to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning
MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog
MIRA
21 May 24
of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results to differ materially and adversely from
bal64f
MIRA
20 May 24
materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's
- Prev
- 1
- Next